Researchers at Stanford University have developed a software that applies correction algorithms on sequence data from cell-free DNA (cfDNA) in blood samples to estimate total T and B cell counts.
Stanford researchers have developed a novel CRISPR-based method, Oligo-LiveFISH, for generating large-scale pools of synthetic RNA oligos that enable multiplexed targeting, imaging, and manipulation of genomic regions in living cells.
Stanford researchers have developed a new method for producing high-quality lead-germanium-selenide (PbGeSe) thin films with improved optical performance and uniformity.
Stanford scientists have developed a frequency-based power control method that enables RF amplifiers to double their output power within 500 nanoseconds using only passive components.
The Stanford team developed a versatile injectable alginate-collagen hydrogel, a significant advancement in regenerative medicine and targeted therapeutic delivery.
Stanford scientists have discovered a DNA methylation signature on circulating tumor DNA (ctDNA) that can distinguish between the aggressive Leiomyosarcoma (LMS) from its benign counterpart leiomyoma (LM) in the uterus.
Researchers at Stanford have developed a novel T cell engineering platform that leverages constitutively active interleukin-9 receptor (IL-9R) signaling to improve the efficacy and scalability of immunotherapies for solid tumors.
Stanford scientists have developed a new DNA-based technology that allows therapeutic genes to be maintained in human cells for extended periods without altering the cell's chromosomes.
Stanford researchers have developed the Large-scale Electrophysiology Amplification Platform (LEAP), a wireless, label-free optical system for monitoring the electrical activity of neurons and heart cells.
Researchers at Stanford have developed an innovative, non-invasive thermal treatment to recover the lost capacity of used lithium-ion batteries (LIBs), offering a scalable and cost-effective solution to the environmental challenges posed by battery waste.
Stanford researchers developed and patented a multiplexed immunohistochemistry method called multiplexed ion beam imaging (MIBI), which uses antibodies tagged with non-biological elemental isotopes (e.g. rare earth elements) and secondary ion mass spectroscopy.
Stanford scientists have developed fully human CD19-targeted CAR T cells designed to overcome the limitations of current CAR T cell therapies, particularly in treating low CD19 density blood cancers.